Literature DB >> 11254227

Cardiovascular responses to arginine vasopressin blockade during acute hypoxemia in the llama fetus.

E A Herrera1, R A Riquelme, E M Sanhueza, C Gajardo, J T Parer, A J Llanos.   

Abstract

The fetal llama has a marked increase in the peripheral vascular resistance and no augmentation of brain blood flow during hypoxemia. In spite of the substantial plasma arginine-vasopressin (AVP) increase during hypoxemia, up to 8 times greater than in fetal sheep, there are no changes of carotid and femoral blood flows during hypoxemia with a V1 receptor blockade, as is seen in the fetal sheep. The aim of this study was to assess the role of AVP function in mediating the combined ventricular output and organ blood flow in the hypoxemic llama fetus. Six fetal llamas at 0.65 of gestation were instrumented under general anesthesia, and cardiorespiratory responses and blood flows determined under normoxemic and hypoxemic conditions. The AVP effect was determined using a V1 antagonist during normoxemic and hypoxemic conditions. Organ blood flows were measured with the radioactive microsphere technique. No significant differences in organ blood flow or in their vascular resistances were seen between the control and treated fetuses during hypoxemia. We conclude that V1 blockade did not have any important role in the cardiovascular response to acute hypoxemia in the llama fetus, in contrast with lowland fetuses. AVP may be playing a role in other regions, possibly in kidney or lung, during hypoxemia.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11254227     DOI: 10.1089/15270290050144172

Source DB:  PubMed          Journal:  High Alt Med Biol        ISSN: 1527-0297            Impact factor:   1.981


  1 in total

1.  Regional brain blood flow and cerebral hemispheric oxygen consumption during acute hypoxaemia in the llama fetus.

Authors:  Aníbal J Llanos; Raquel A Riquelme; Emilia M Sanhueza; Emilio Herrera; Gertrudis Cabello; Dino A Giussani; Julian T Parer
Journal:  J Physiol       Date:  2002-02-01       Impact factor: 5.182

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.